Arcutis Biotherapeutics vs Tarsus Pharmaceuticals
ARQT and TARS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARQT and TARS compare
Arcutis Biotherapeutics is the larger company, worth 1.2 times as much as Tarsus Pharmaceuticals ($4.0B against $3.3B).
Tarsus Pharmaceuticals grew revenue faster over the last twelve months (105% versus 76.1% for Arcutis Biotherapeutics).
Arcutis Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of 6.1% compared with −7.7% at Tarsus Pharmaceuticals.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARQT | TARS |
|---|---|---|
| Size and price | ||
| Market cap | $4.0B | $3.3B |
| Share price | $32.07 | $74.85 |
| Change, 1 year | 26.8% | 10.9% |
| Change, 5 years | 45.4% | 169% |
| Beta (5Y) | 0.87 | 0.63 |
| Employees | 354 | 370 |
| StockData Score | ||
| Total score | 11 | 11 |
| Valuation score | 0 | 1 (better) |
| Growth score | 4 (better) | 3 |
| Performance score | 4 (better) | 3 |
| Health score | 3 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 146× | – |
| P/S | 8.7× | 5.4× (better) |
| P/B | 18.3× | 9.5× (better) |
| EV/EBITDA | 114× | – |
| P/FCF | 103× | 58.7× (better) |
| FCF yield | 0.97% | 1.7% (better) |
| Fair value | $5.37 | $75.56 |
| Margin of safety | −497% | 0.94% (better) |
| Growth | ||
| Revenue growth (TTM) | 76.1% | 105% (better) |
| Profitability | ||
| Gross margin | 91.1% | – |
| Operating margin | 7.4% (better) | −8.0% |
| Net margin | 6.1% (better) | −7.7% |
| FCF margin | 8.4% | 9.2% (better) |
| Return on equity | 15.9% (better) | −13.7% |
| Return on invested capital | 36.9% | – |
| Financial health | ||
| Debt / equity | 0.49 | 0.21 (better) |
| Net debt / EBITDA | −3.79 | – |
| Interest coverage | 2.5× (better) | −5.5× |
| Current ratio | 2.92 | 3.20 (better) |
| Altman Z-score | 7.71 | 7.91 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 105% | 110% |
| Held by insiders | 9.3% | 3.1% |
| Insider net buying, 12 months | −$15.2M (better) | −$20.0M |
| Short interest, % of float | 19.0% | 14.3% |
Go deeper
- ARQT stock overview
- ARQT income statement
- ARQT valuation and score
- TARS stock overview
- TARS income statement
- TARS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.